Functional involvement of endothelial lipase in hepatitis B virus infection.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
25
06
2022
accepted:
05
04
2023
medline:
4
9
2023
pubmed:
1
9
2023
entrez:
1
9
2023
Statut:
epublish
Résumé
HBV infection causes chronic liver disease and leads to the development of HCC. To identify host factors that support the HBV life cycle, we previously established the HC1 cell line that maintains HBV infection and identified host genes required for HBV persistence. The present study focused on endothelial lipase (LIPG), which binds to heparan sulfate proteoglycans (HSPGs) in the cell membrane. We found HBV infection was impaired in humanized liver chimeric mouse-derived hepatocytes that were transduced with lentivirus expressing short hairpin RNA against LIPG. Long-term suppression of LIPG combined with entecavir further suppressed HBV replication. LIPG was shown to be involved in HBV attachment to the cell surface by using 2 sodium taurocholate cotransporting peptide (NTCP)-expressing cell lines, and the direct interaction of LIPG and HBV large surface protein was revealed. Heparin and heparinase almost completely suppressed the LIPG-induced increase of HBV attachment, indicating that LIPG accelerated HBV attachment to HSPGs followed by HBV entry through NTCP. Surprisingly, the attachment of a fluorescently labeled NTCP-binding preS1 probe to NTCP-expressing cells was not impaired by heparin, suggesting the HSPG-independent attachment of the preS1 probe to NTCP. Interestingly, attachment of the preS1 probe was severely impaired in LIPG knockdown or knockout cells. Inhibitors of the lipase activity of LIPG similarly impaired the attachment of the preS1 probe to NTCP-expressing cells. LIPG participates in HBV infection by upregulating HBV attachment to the cell membrane by means of 2 possible mechanisms: increasing HBV attachment to HSPGs or facilitating HSPG-dependent or HSPG-independent HBV attachment to NTCP by its lipase activity.
Sections du résumé
BACKGROUND
HBV infection causes chronic liver disease and leads to the development of HCC. To identify host factors that support the HBV life cycle, we previously established the HC1 cell line that maintains HBV infection and identified host genes required for HBV persistence.
METHODS
The present study focused on endothelial lipase (LIPG), which binds to heparan sulfate proteoglycans (HSPGs) in the cell membrane.
RESULTS
We found HBV infection was impaired in humanized liver chimeric mouse-derived hepatocytes that were transduced with lentivirus expressing short hairpin RNA against LIPG. Long-term suppression of LIPG combined with entecavir further suppressed HBV replication. LIPG was shown to be involved in HBV attachment to the cell surface by using 2 sodium taurocholate cotransporting peptide (NTCP)-expressing cell lines, and the direct interaction of LIPG and HBV large surface protein was revealed. Heparin and heparinase almost completely suppressed the LIPG-induced increase of HBV attachment, indicating that LIPG accelerated HBV attachment to HSPGs followed by HBV entry through NTCP. Surprisingly, the attachment of a fluorescently labeled NTCP-binding preS1 probe to NTCP-expressing cells was not impaired by heparin, suggesting the HSPG-independent attachment of the preS1 probe to NTCP. Interestingly, attachment of the preS1 probe was severely impaired in LIPG knockdown or knockout cells. Inhibitors of the lipase activity of LIPG similarly impaired the attachment of the preS1 probe to NTCP-expressing cells.
CONCLUSIONS
LIPG participates in HBV infection by upregulating HBV attachment to the cell membrane by means of 2 possible mechanisms: increasing HBV attachment to HSPGs or facilitating HSPG-dependent or HSPG-independent HBV attachment to NTCP by its lipase activity.
Identifiants
pubmed: 37655967
doi: 10.1097/HC9.0000000000000206
pii: 02009842-202309010-00011
pmc: PMC10476801
pii:
doi:
Substances chimiques
Heparan Sulfate Proteoglycans
0
Heparin
9005-49-6
Lipase
EC 3.1.1.3
Lipg protein, mouse
EC 3.1.1.3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Références
J Lipid Res. 2004 Nov;45(11):2080-7
pubmed: 15342690
Nat Genet. 1999 Apr;21(4):424-8
pubmed: 10192396
N Engl J Med. 2019 May 23;380(21):2041-2050
pubmed: 31116920
J Biol Chem. 2005 Nov 4;280(44):36551-9
pubmed: 16109723
Gastroenterology. 2014 Jul;147(1):48-64
pubmed: 24768844
Glycobiology. 2001 Jun;11(6):91R-98R
pubmed: 11445547
Hepatol Commun. 2022 Sep;6(9):2441-2454
pubmed: 35691027
Biochem Biophys Res Commun. 2014 Jan 17;443(3):808-13
pubmed: 24342612
Hepatology. 2007 Dec;46(6):1759-68
pubmed: 18046710
Antiviral Res. 2018 Mar;151:4-7
pubmed: 29309795
PLoS One. 2018 Apr 10;13(4):e0194797
pubmed: 29634782
PLoS One. 2021 Feb 4;16(2):e0246313
pubmed: 33539396
FASEB J. 2004 Dec;18(15):1891-3
pubmed: 15456739
J Biol Chem. 1999 May 14;274(20):14170-5
pubmed: 10318835
Elife. 2012 Nov 13;1:e00049
pubmed: 23150796
Biochem Biophys Res Commun. 2000 May 27;272(1):90-3
pubmed: 10872808
J Biol Chem. 1982 Jul 10;257(13):7770-7
pubmed: 7085648
Cells. 2020 Jun 18;9(6):
pubmed: 32570893
Histol Histopathol. 2018 Jan;33(1):1-10
pubmed: 28540715
J Biol Chem. 2003 Sep 5;278(36):34331-8
pubmed: 12810721
Hepatology. 2013 Mar;57(3):985-94
pubmed: 23161433
Antiviral Res. 2020 Oct;182:104925
pubmed: 32866519